false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Podocyte-Directed VEGFC Gene Therapy for Diabetes
Podocyte-Directed VEGFC Gene Therapy for Diabetes
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The talk explored VEGF-C gene therapy as a potential treatment for diabetic kidney disease. The glomerular endothelial glycocalyx is a key part of the filtration barrier, and diabetes disrupts this barrier, causing albumin leakage. While excess VEGF-A can make glomerular vessels abnormally permeable, experiments showed that VEGF-C counteracts this effect and helps preserve the glycocalyx, possibly by promoting its synthesis or moving preformed components to the cell surface.<br /><br />In diabetic mouse models, VEGF-C reduced glomerular albumin permeability and albuminuria. Researchers then used an AAV vector to deliver human VEGF-C, with expression enriched in glomeruli. Treatment improved these kidney outcomes and increased glycocalyx depth, although expression also occurred in the liver and lungs. The findings support VEGF-C as a promising therapeutic target, including for non-monogenic disease, but further work is needed to optimize delivery, dose, and target specificity and to assess circulating VEGF-C levels.
Asset Caption
Rebecca R. Foster, PhD
Meta Tag
Speaker
Rebecca Foster
Keywords
VEGF-C
diabetic kidney disease
glomerular glycocalyx
albuminuria
gene therapy
AAV vector
Rebecca Foster
×
Please select your language
1
English